Results from the first-in-human (FIH) phase I study of RO5520985 (RG7221), a novel bispecific human anti-ANG-2/anti-VEGF-A antibody, administered as an intravenous infusion to patients with advanced solid tumors.
Manuel Hidalgo
Research Funding - Roche
Christophe Le Tourneau
No relevant relationships to disclose
Christophe Massard
Consultant or Advisory Role - Roche
Research Funding - Roche
Valentina Boni
No relevant relationships to disclose
Emiliano Calvo
No relevant relationships to disclose
Joan Albanell
Consultant or Advisory Role - Roche (U)
Research Funding - Roche
Alvaro Taus
No relevant relationships to disclose
Marie-Paule Sablin
No relevant relationships to disclose
Andrea Varga
No relevant relationships to disclose
Ratislav Bahleda
No relevant relationships to disclose
Oliver Krieter
Employment or Leadership Position - Roche
Stock Ownership - Roche
Lada Markovtsova
Employment or Leadership Position - Roche
Stock Ownership - Roche
David Carlile
Employment or Leadership Position - Roche
Stock Ownership - Roche
Angelika Lahr
Employment or Leadership Position - Roche
Tapan Nayak
Employment or Leadership Position - Roche
Katharina Lechner
Employment or Leadership Position - Roche
Astrid Koehler
Employment or Leadership Position - Roche
Stock Ownership - Roche
Ingrid Van Uffelen
Employment or Leadership Position - Roche
Maria Martinez Garcia
No relevant relationships to disclose